Integrated Medical Development   Report issue

For profit Phase 3
Founded: Princeton Junction NJ United States (2009)

Organization Overview

First Clinical Trial
2018
NCT03439072
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Integrated Medical Development

Active Ingredients

Drugs in Phase 3 Trials (1)

glucagon (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 3)

Hypoglycemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 1